Patent details

EP3980047 Title: INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS

Basic Information

Publication number:
EP3980047
PCT Application Number:
US2020036091
Type:
European Patent Granted for LU
Legal Status:
Unitary Effect Registered
Application number:
EP207499963
PCT Publication Number:
WO2020247607
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS
French Title of Invention:
TRAITEMENT DES MALADIES INFLAMMATOIRES AVEC INHIBITEURS DU COMPLÉMENT
German Title of Invention:
BEHANDLUNG EINER ENTZÜNDLICHEN ERKRANKUNG MIT KOMPLEMENTINHIBITOREN
SPC Number:

Unitary Effect

Unitary Effect Requested:
Yes
Unitary Effect Request Filing Date:
14/02/2024
Link to UPP Register:
European Patent Register
Unitary Effect Request Withdrawal Date:
Unitary Effect Status:
Unitary Effect Registered
Unitary Effect Acceptance Decision Date:
22/02/2024
Unitary Effect Rejection Decision Date:
Unitary Effect Date:
14/02/2024
Unitary Effect Registration Date:
22/02/2024
Unitary Effect Re-establishment of rights Filing Date:
Unitary Effect Re-establishment of rights EPO Decision :
Unitary Effect Re-establishment of rights EPO Decision Date:
Explanatory Text UE:
Safety Net Request Date:
Safety Net Decision Date:
Safety Net Decision Outcome:
SPC Number:

Dates

Filing date:
04/06/2020
Grant date:
14/02/2024
EP Publication Date:
13/04/2022
PCT Publication Date:
10/12/2020
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
14/02/2024
EP B1 Publication Date:
14/02/2024
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
04/06/2040
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
19/06/2025
 
 

Name:
UCB Holdings, Inc.
Address:
1950 Lake Park Drive, Smyrna, GA 30080, United States (US)

History of Owners

From:
07/02/2024
To:
19/06/2025

Name:
RA Pharmaceuticals, Inc.
Address:
87 Cambridge Park Drive, Cambridge, MA 02140, United States (US)

Inventor

1

Name:
VADYSIRISACK, Douangsone D.
Address:
United States (US)

2

Name:
SAYEGH, Camil
Address:
United States (US)

3

Name:
ZHU, Nanqun
Address:
United States (US)

4

Name:
DROUOT, Laurent
Address:
France (FR)

5

Name:
DUDA, Petra
Address:
United States (US)

6

Name:
BOYER, Olivier
Address:
France (FR)

7

Name:
RICARDO, Alonso
Address:
United States (US)

8

Name:
FARZANEH-FAR, Ramin
Address:
United States (US)

Priority

1

Priority Number:
201962856906 P
Priority Date:
04/06/2019
Priority Country:
United States (US)

2

Priority Number:
201962899872 P
Priority Date:
13/09/2019
Priority Country:
United States (US)

3

Priority Number:
201962926874 P
Priority Date:
28/10/2019
Priority Country:
United States (US)

4

Priority Number:
2002201
Priority Date:
04/03/2020
Priority Country:
France (FR)

5

Priority Number:
202062984827 P
Priority Date:
04/03/2020
Priority Country:
United States (US)

Classification

IPC classification:
A61K 38/12; A61P 21/00;

Publication

European Patent Bulletin

1

Issue number:
202407
Publication date:
14/02/2024
Description:
Grant (B1)

2

Issue number:
202530
Publication date:
23/07/2025
Description:
Transfer of Rights

3

Issue number:
202412
Publication date:
20/03/2024
Description:
Unitary Effect Request Receipt

4

Issue number:
202413
Publication date:
27/03/2024
Description:
Unitary Effect Request Acceptance

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages